CytoDyn (OTC: CYDY) to Hold Investment Community Conference Call on December 17, 2019

VANCOUVER, Washington, Dec. 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer, will host an investment community conference call to provide an update on the Company.

Date: Tuesday, December 17, 2019
Time: 4:00 p.m. ET / 1:00 p.m. PT
Dial In: 877-407-2986 U.S. and Canada 201-378-4916 International

A live audio webcast may also be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link:

https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/33784/indexl.html

A replay of the conference call will be available until January 16, 2020. To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international) and enter conference identification number 13695017.

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.